This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look: Checking in with a prescriber of Abbvie's IMBRUVICA (ibrutinib) for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Ticker(s): ABBVWho's the expert?
Institution: Detroit Medical Center
- Board Certified Hematologist and oncologist
- Currently manages 120 CLL patients and 30 SLL patients
- Has prescribed Imbruvica to as a first line treatment to ~40 patients
Interview GoalTo discuss the standard of care and the use of Abbvie's IMBRUVICA (ibrutinib), a BTK inhibitor for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
